Bristol Myers Squibb reports double-digit growth in Q3

US-based Bristol Myers Squibb's revenue in the third quarter of the year has gone up 10 percent to USD 11.6bn and surpassed analyst estimates, reports Bloomberg News.

Photo: Brian Snyder/Reuters/Ritzau Scanpix

The US-based pharmaceutical giant Bristol Myers Squibb has seen progress in the year's third quarter, increasing product revenue for several of its drugs, it reported in a press release on Wednesday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs